Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 52

Sort by

Sort Order Select

Journal Articles

Evidence of Improved Knowledge and Skills Among Hematologists/Oncologists Participating in Online CME-Certified Activities

Lauren Willis, Emily S. Van Laar, Tristin Abair, Megan Whitney, Caitlin Costello, Amrita Y. Krishnan, Sagar Lonial, Sandra Kurtin, Joseph Mikhael, Ola Landgren

Blood (2021) 138 (Supplement 1): 4958.

https://doi.org/10.1182/blood-2021-145375

Published: 2021

Journal Articles

High-Risk Gene Expression Subtype Provides Molecular Basis for Different Clinical Presentation of Primary and Secondary Plasma Cell Leukemia

Sheri Skerget, Daniel Penaherrera, Joseph Mikhael, Jonathan J Keats

Blood (2021) 138 (Supplement 1): 726.

https://doi.org/10.1182/blood-2021-148138

Published: 2021

Journal Articles

Pilot Trial of the My Hematology Oncology Patient Experience (MyHOPE™) for Multiple Myeloma (MM) Digital Solution in Patients with MM

Noopur S. Raje, MD, Omar Nadeem, MD, Joseph Mikhael, MD FRCPC, MD, Catherine Ludwig, MB BChir, Amit Agarwal, MD PhD, Judith Inumerable, PGC, Teng J. Ong, MD, Sundar Jagannath, MD

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-141591

Published: 2020

Journal Articles

Understanding Root Causes Contributing to Real-World Racial Disparities in Multiple Myeloma Care: Insights from a Mixed-Methods Study Utilizing Tethered Patient-Provider Surveys and Chart Reviews

Joseph Mikhael, MD FRCPC, MD, Anne Jacobson, MS, Jeffrey D Carter, PhD, Tamar Sapir, PhD

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-136750

Published: 2020

Journal Articles

Real-World Renal Function Among Patients with Multiple Myeloma in the United States

Joseph Mikhael, MD FRCPC, MD, Erin Singh, Megan Rice, ScD, MPH

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-136630

Published: 2020

Journal Articles

Depth of Response and Response Kinetics of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Ikema Interim Analysis

Thomas Martin, MD, Joseph Mikhael, MD FRCPC, MD, Roman Hajek, MD, Kihyun Kim, MD PhD, Kenshi Suzuki, MD PhD, Cyrille Hulin, MD, Mamta Garg, MD FRCP, FRCPath, Hang Quach, MDFRACP,FRCPA,MBBS, Hanlon Sia, Anup George, Tatiana Konstantinova, MD PhD, Marie-Laure Risse, Gaelle Asset, Sandrine Macé, Helgi van de Velde, MD PhD, Philippe Moreau, MD

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-137681

Published: 2020

Journal Articles

The Global State of Hematopoietic Stem Cell Transplantation for Multiple Myeloma: An Analysis of the Worldwide Network of Blood and Marrow Transplantation (WBMT) Database and the Global Burden of Disease Study

Blood (2019) 134 (Supplement_1): 412.

https://doi.org/10.1182/blood-2019-126837

Published: 2019

Journal Articles

The Relationship between Baseline Biomarkers and Efficacy of Isatuximab in Combination with Pomalidomide and Dexamethasone in RRMM: Insights from Phase 1 and Phase 3 Studies

Paul G. Richardson, MD, Joseph Mikhael, MD FRCPC, MD, Thierry Facon, MD, William I. Bensinger, Sandrine Macé, Marielle Chiron, Helgi van de Velde, MD PhD, Frank Campana, MD, Li Liu, Michel Attal, MD PhD

Blood (2019) 134 (Supplement_1): 3179.

https://doi.org/10.1182/blood-2019-128071

Published: 2019

Journal Articles

A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma

Joseph Mikhael, Paul Richardson, Saad Z. Usmani, Noopur Raje, William Bensinger, Chatchada Karanes, Frank Campana, Dheepak Kanagavel, Franck Dubin, Qianying Liu, Dorothée Semiond, Kenneth Anderson

Blood (2019) 134 (2): 123–133.

https://doi.org/10.1182/blood-2019-02-895193

Published: 2019

Journal Articles

Patient Treatment Preferences for Relapsed/Refractory Multiple Myeloma: Are Patients Willing to Trade Off Efficacy for Tolerability?

Daniel Auclair, PhD, Carol Mansfield, PhD, Ajai Chari, MD, Craig E. Cole, MD, Mark A. Fiala, BS, Jonathan L Kaufman, MD, Gregory Orloff, MD, David S Siegel, MD PhD, Jeffrey A Zonder, MD, Brennan Mange, Jennifer Yesil, MS, Mehul Dalal, PhD, Joseph Mikhael, MD FRCPC, MD

Blood (2018) 132 (Supplement 1): 614.

https://doi.org/10.1182/blood-2018-99-113087

Published: 2018

Journal Articles

Predicting Risk of Venous Thromboembolism in Multiple Myeloma: The Impede VTE Score

Kristen M. Sanfilippo, MD, Suhong Luo, MS, Tzu-Fei Wang, MD, Tanya Wildes, MD, Joseph Mikhael, MD FRCPC, MD, Jesse W. Keller, MD MPHS, Theodore S. Thomas, MD MPHS, Kenneth R. Carson, MD PhD, Brian F. Gage, MD MSc

Blood (2018) 132 (Supplement 1): 141.

https://doi.org/10.1182/blood-2018-99-116300

Published: 2018

Journal Articles

Determinants of Hematology-Oncology Trainee's Post-Fellowship Career Pathways with a Focus on Non-Malignant Hematology

Ariela L. Marshall, MD, Sarah Jenkins, MS, Joseph Mikhael, MD MD FRCPC, Scott D. Gitlin, MD

Blood (2017) 130 (Supplement 1): 3365.

https://doi.org/10.1182/blood.V130.Suppl_1.3365.3365

Published: 2017

Journal Articles

Understanding the Preferences of Patients and Caregivers for Relapsed/Refractory Multiple Myeloma Treatment: A Mixed-Mode Patient-Centric Approach

Daniel Auclair, PhD, Carol Mansfield, PhD, Ajai Chari, MD, Craig E. Cole, MD, Mark A. Fiala, BS, Jonathan L. Kaufman, MD, Gregory Orloff, MD, David Siegel, MD PhD, Jeff A. Zonder, MD, Brennan Mange, Jennifer Yesil, MS, Mehul Dalal, PhD, Joseph Mikhael, MD

Blood (2017) 130 (Supplement 1): 5662.

https://doi.org/10.1182/blood.V130.Suppl_1.5662.5662

Published: 2017

Journal Articles

Updated Results from a Phase Ib Study of Isatuximab Plus Pomalidomide (Pom) and Dexamethasone (dex) in Relapsed/Refractory Multiple Myeloma (RRMM)

Paul G Richardson, MD, Joseph Mikhael, MD, Saad Z Usmani, MD, Noopur Raje, MD, William Bensinger, MD, Dheepak Kanagavel, MD PhD, Lei Gao, Samira Ziti-Ljajic, Kenneth C Anderson, MD

Blood (2017) 130 (Supplement 1): 1887.

https://doi.org/10.1182/blood.V130.Suppl_1.1887.1887

Published: 2017

Journal Articles

Carfilzomib in Relapsed or Refractory Multiple Myeloma Patients with Early or Late Relapse Following Prior Therapy: A Subgroup Analysis of the Randomized Phase 3 Aspire and Endeavor Trials

Maria-Victoria Mateos, Hartmut Goldschmidt, MD, Jesus F San Miguel, MD PhD, Joseph Mikhael, MD, Lucy DeCosta, MSc, Lifen Zhou, Mihaela Obreja, Julie Blaedel, Zsolt Szabo, MD, Xavier Leleu, MD PhD

Blood (2017) 130 (Supplement 1): 3120.

https://doi.org/10.1182/blood.V130.Suppl_1.3120.3120

Published: 2017

Journal Articles

Phase 1 Study of Venetoclax in Combination with Dexamethasone As Targeted Therapy for t(11;14) Relapsed/Refractory Multiple Myeloma

Jonathan L. Kaufman, MD, Cristina J. Gasparetto, MD, Joseph Mikhael, MD, Philippe Moreau, MDPhD, Cyrille Touzeau, MD PhD, Ravi Vij, MDMBA, Thierry Facon, MD, Brigitte Pegourie, MD, Lofti Benboubker, MD, Lawrence H. Boise, PhD, Stefanie Alzate, MSc, Martin Dunbar, DRPH, MS, Jia Jia, PhD MBA, Kevin J. Freise, PhD, Maria Verdugo, MD, Jeremy Ross, PhD MBA, Paulo Maciag, MD PhD, Shaji K Kumar, MD

Blood (2017) 130 (Supplement 1): 3131.

https://doi.org/10.1182/blood.V130.Suppl_1.3131.3131

Published: 2017

Journal Articles

Relapsed or Refractory Multiple Myeloma Patients Treated with Second-Line Carfilzomib and Categorized By Prior Exposure to Bortezomib: A Subgroup Analysis of the Randomized Phase 3 Aspire and Endeavor Trials

Maria-Victoria Mateos, Hartmut Goldschmidt, MD, Jesus F San Miguel, MD PhD, Joseph Mikhael, MD, Lifen Zhou, Mihaela Obreja, Julie Blaedel, Karim Saad Iskander, Xavier Leleu, MD PhD

Blood (2017) 130 (Supplement 1): 1840.

https://doi.org/10.1182/blood.V130.Suppl_1.1840.1840

Published: 2017

Journal Articles

Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma

Blood (2017) 130 (22): 2401–2409.

https://doi.org/10.1182/blood-2017-06-788786

Published: 2017

Includes: Supplemental data

Journal Articles

Pee no more? Urine light chains down the drain

Joseph Mikhael

Blood (2016) 128 (25): 2873–2874.

https://doi.org/10.1182/blood-2016-10-746883

Published: 2016

Journal Articles

Treatment with Bortezomib (Bor) Based Therapy Followed By Autologous Stem Cell Transplantation (SCT) Improves Outcomes in Light Chain Amyloidosis (AL)

Tania Jain, M.B.,B.S, Shu Ting Kung, MD, Vishal Shah, Pharm.D., R.Ph., Amylou Constance Dueck, PhD, Heidi E. Kosiorek, MS, Joseph Mikhael, MD, P. Leif Bergsagel, MD, Craig B. Reeder, MD, Pierre Noel, MD, Roberta H. Adams, MD, Susan Luft, M.S., R.N., Angela Mayo, P.A.-C., M.S., A. Keith Stewart, M.B., Ch.B., Rafael Fonseca, MD

Blood (2016) 128 (22): 4629.

https://doi.org/10.1182/blood.V128.22.4629.4629

Published: 2016

NARROW

Evidence of Improved Knowledge and Skills Among Hematologists/Oncologists Participating in Online CME-Certified Activities

High-Risk Gene Expression Subtype Provides Molecular Basis for Different Clinical Presentation of Primary and Secondary Plasma Cell Leukemia

Pilot Trial of the My Hematology Oncology Patient Experience (MyHOPE™) for Multiple Myeloma (MM) Digital Solution in Patients with MM

Understanding Root Causes Contributing to Real-World Racial Disparities in Multiple Myeloma Care: Insights from a Mixed-Methods Study Utilizing Tethered Patient-Provider Surveys and Chart Reviews

Real-World Renal Function Among Patients with Multiple Myeloma in the United States

Depth of Response and Response Kinetics of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Ikema Interim Analysis

The Global State of Hematopoietic Stem Cell Transplantation for Multiple Myeloma: An Analysis of the Worldwide Network of Blood and Marrow Transplantation (WBMT) Database and the Global Burden of Disease Study

The Relationship between Baseline Biomarkers and Efficacy of Isatuximab in Combination with Pomalidomide and Dexamethasone in RRMM: Insights from Phase 1 and Phase 3 Studies

A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma

Patient Treatment Preferences for Relapsed/Refractory Multiple Myeloma: Are Patients Willing to Trade Off Efficacy for Tolerability?

Predicting Risk of Venous Thromboembolism in Multiple Myeloma: The Impede VTE Score

Determinants of Hematology-Oncology Trainee's Post-Fellowship Career Pathways with a Focus on Non-Malignant Hematology

Understanding the Preferences of Patients and Caregivers for Relapsed/Refractory Multiple Myeloma Treatment: A Mixed-Mode Patient-Centric Approach

Updated Results from a Phase Ib Study of Isatuximab Plus Pomalidomide (Pom) and Dexamethasone (dex) in Relapsed/Refractory Multiple Myeloma (RRMM)

Carfilzomib in Relapsed or Refractory Multiple Myeloma Patients with Early or Late Relapse Following Prior Therapy: A Subgroup Analysis of the Randomized Phase 3 Aspire and Endeavor Trials

Phase 1 Study of Venetoclax in Combination with Dexamethasone As Targeted Therapy for t(11;14) Relapsed/Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma Patients Treated with Second-Line Carfilzomib and Categorized By Prior Exposure to Bortezomib: A Subgroup Analysis of the Randomized Phase 3 Aspire and Endeavor Trials

Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma

Pee no more? Urine light chains down the drain

Treatment with Bortezomib (Bor) Based Therapy Followed By Autologous Stem Cell Transplantation (SCT) Improves Outcomes in Light Chain Amyloidosis (AL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only